Trial
NCT04880577
Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple Sclerosis
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Massachusetts General Hospital
Collaborators
Gilead Sciences
Condition
Multiple Sclerosis, Relapsing-Remitting
Intervention
TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY]
Why stopped
Funding
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-11-15